Health ❯Healthcare ❯Obesity ❯Weight Management

Medications

Pharmacology Drug Development Hormones Research Studies Pharmaceuticals Adverse Effects Diabetes Obesity Clinical Studies

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

The phase 1 data reveal sustained weight reduction with tolerable gastrointestinal effects ahead of planned 2026 phase 3 trials.